EP-1013 manufacturers
- EP1013
-
- $759.00 / 25mg
-
2026-04-22
- CAS:223568-55-6
- Min. Order:
- Purity:
- Supply Ability: 10g
- EP1013
-
- $759.00 / 25mg
-
2025-07-19
- CAS:223568-55-6
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | EP-1013 Basic information |
| Product Name: | EP-1013 | | Synonyms: | EP-1013;(3S)-5-Fluoro-3-[[(2S)-3-methyl-1-oxo-2-[[(phenylmethoxy)carbonyl]amino]butyl]amino]-4-oxopentanoic acid;F 1013;Z-VD-FMK (mixture of isomers);Pentanoic acid, 5-fluoro-3-[[(2S)-3-methyl-1-oxo-2-[[(phenylmethoxy)carbonyl]amino]butyl]amino]-4-oxo-, (3S)-;EP1013 (F1013);EP1013,EP-1013;abs821708 | | CAS: | 223568-55-6 | | MF: | C18H23FN2O6 | | MW: | 382.38 | | EINECS: | | | Product Categories: | | | Mol File: | 223568-55-6.mol |  |
| | EP-1013 Chemical Properties |
| Boiling point | 639.8±55.0 °C(Predicted) | | density | 1.258±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : ≥ 60 mg/mL (156.91 mM) | | form | Solid | | pka | 3.92±0.19(Predicted) | | color | White to off-white |
| | EP-1013 Usage And Synthesis |
| Uses | EP1013 (F1013) is a broad-spectrum caspase selective inhibitor, used in the research of type 1 diabetes[1]. | | in vivo | EP1013 (1, 3, 10 mg/kg) significantly improves marginal islet mass function. Two animals in the 10 mg/kg EP1013 treatment group exhibit primary islet graft nonfunction, but the diabetes reversal rate for this group is not significantly different from the 3 mg/kg EP1013, 1 mg/kg EP1013, or 10 mg/kg zVAD groups. EP1013 therapy enhances functional syngeneic islet mass and promotes longevity of islet graft function[1]. | | IC 50 | Caspase | | References | [1] Emamaullee JA, et al. The caspase selective inhibitor EP1013 augments human islet graft function and longevity in marginal mass islet transplantation in mice. Diabetes. 2008 Jun;57(6):1556-66. DOI:10.2337/db07-1452 |
| | EP-1013 Preparation Products And Raw materials |
|